ABOUT
US

45%

seniors aged 85and over sufferfrom AD

10%

people aged 65and over have AD

Despite decades of research, scientists have not yet unlocked the cure to Alzheimer’s disease (AD) or its prevention. Until they do, its impact increases every year. It is estimated that 45% of seniors aged 85 and over suffer from AD and 10% of people aged 65 and over have AD.

Neuronix is a medical device company that has taken a novel approach to treatment of AD. As opposed to a pharmaceutical solution, Neuronix has developed a patented technology, that concurrently combines Transcranial Magnetic Stimulation (TMS) with Cognitive Training (CgT). Our device, the neuroADTM Therapy System is the only medical device in the world approved for treatment of mild to moderate AD. The system has received CE mark approval and is commercially available in Europe, Australia and Asia, and is pending FDA clearance in the United States.

Since it was founded in 2008, Neuronix has carried out multiple clinical studies that have confirmed the safety and efficacy of its solution, including a pivotal, multi-center clinical study in the United States. Neuronix’s scientific advisory board consists of leading physicians and researchers in the field who continuously guide the company.

While the neuroADTM Therapy System cannot cure AD, it has been shown to improve the cognitive, functional and behavioral capabilities of patients with AD. Treated patients have reported that they are able to read again, paint again, walk down the street without getting disoriented and reconnect with their families. These success stories are the driving force behind Neuronix.